EA200501323A1 - Получение эритроцитов с модифицированным уровнем экспрессии антигенов групп крови и их применение в контроле качества реагентов для определения группы крови - Google Patents

Получение эритроцитов с модифицированным уровнем экспрессии антигенов групп крови и их применение в контроле качества реагентов для определения группы крови

Info

Publication number
EA200501323A1
EA200501323A1 EA200501323A EA200501323A EA200501323A1 EA 200501323 A1 EA200501323 A1 EA 200501323A1 EA 200501323 A EA200501323 A EA 200501323A EA 200501323 A EA200501323 A EA 200501323A EA 200501323 A1 EA200501323 A1 EA 200501323A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood
reagents
quality
control
antigens
Prior art date
Application number
EA200501323A
Other languages
English (en)
Other versions
EA011481B1 (ru
Inventor
Стивен Майкл Генри
Лисса Гуинет Гилливер
Original Assignee
Киуи Индженьюити Лимитид
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Киуи Индженьюити Лимитид filed Critical Киуи Индженьюити Лимитид
Publication of EA200501323A1 publication Critical patent/EA200501323A1/ru
Publication of EA011481B1 publication Critical patent/EA011481B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Способ получения эритроцитов, экспрессирующих уменьшенные уровни антигенов групп крови, с использованием по меньшей мере одного модифицирующего иммунодоминантный сахар фермента, например альфа-N-ацетилгалактозаминидазы или альфа-галактозидазы. Полученные эритроциты предпочтительно экспрессируют уровень антигена, по существу эквивалентный клинически значимому порогу для этого антигена. Эритроциты, полученные в соответствии с указанным способом, используют для контроля качества реагентов для определения группы крови и калибровки тестирующих систем для обеспечения точных и стандартизованных определений типов групп крови.
EA200501323A 2003-02-17 2004-02-17 Эритроциты, имеющие ферментативно уменьшенный уровень экспрессии антигена группы крови системы аво, способ их получения и применение EA011481B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ52421703 2003-02-17
NZ52777703 2003-08-22
PCT/NZ2004/000030 WO2004072306A1 (en) 2003-02-17 2004-02-17 Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents

Publications (2)

Publication Number Publication Date
EA200501323A1 true EA200501323A1 (ru) 2006-04-28
EA011481B1 EA011481B1 (ru) 2009-04-28

Family

ID=32871331

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501323A EA011481B1 (ru) 2003-02-17 2004-02-17 Эритроциты, имеющие ферментативно уменьшенный уровень экспрессии антигена группы крови системы аво, способ их получения и применение

Country Status (6)

Country Link
US (1) US20070141646A1 (ru)
EP (1) EP1597401A4 (ru)
AU (1) AU2004212104B2 (ru)
CA (1) CA2516123A1 (ru)
EA (1) EA011481B1 (ru)
WO (1) WO2004072306A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287196A1 (en) * 2004-06-11 2007-12-13 Adeka Corporation Enzymatic Modification of Cell-Surface H Antigen by Glycosyltransferases
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
ES2264403B1 (es) 2006-06-22 2007-11-01 Grifols S.A. Medio de suspension de hematies.
FI20075030A0 (fi) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
WO2019084531A1 (en) 2017-10-27 2019-05-02 The Children's Hospital Of Philadelphia MODIFIED RED GLOBES HAVING PHENOTYPES OF RARE ANTIGENS
KR102261148B1 (ko) * 2019-06-27 2021-06-07 아주대학교 산학협력단 ABO 및 RhD 혈액형 표현형이 약화된 시험관법 혈액형 검사의 정도관리용 글루타르알데히드 처리 적혈구 생산방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609627A (en) * 1983-08-01 1986-09-02 New York Blood Center, Inc. Enzymatic conversion of certain sub-type A and AB erythrocytes
DD298348B5 (de) * 1989-11-24 1996-01-25 Universitaetsklinikum Charite Verfahren zur qualitaetskontrolle von Erythozytenkonserven und Bluttransfusionen
US5633130A (en) * 1994-09-08 1997-05-27 The Curators Of The University Of Missouri Buffer system for increasing seroconversion efficiency
US7767415B2 (en) * 2001-09-25 2010-08-03 Velico Medical, Inc. Compositions and methods for modifying blood cell carbohydrates

Also Published As

Publication number Publication date
EA011481B1 (ru) 2009-04-28
CA2516123A1 (en) 2004-08-26
US20070141646A1 (en) 2007-06-21
AU2004212104A1 (en) 2004-08-26
WO2004072306A1 (en) 2004-08-26
WO2004072306A8 (en) 2004-11-11
EP1597401A4 (en) 2007-08-22
AU2004212104B2 (en) 2010-01-28
EP1597401A1 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
Witwer et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications
Niec et al. Lymphatics act as a signaling hub to regulate intestinal stem cell activity
Hapach et al. Phenotypic heterogeneity and metastasis of breast cancer cells
Peuhu et al. SHARPIN regulates collagen architecture and ductal outgrowth in the developing mouse mammary gland
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
DK1774037T3 (da) Analyser og fremgangsmåder, der anvender biomarkører
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
CY1107733T1 (el) Μεθοδος για τον χαρακτηρισμο μιας βιολογικης καταστασης χρησιμοποιωντας βαθμοnομημενα προφιλ γονιδιακης εκφρασης
BRPI0417903A (pt) método de melhorar a detecção de sinal de um componente de parede celular de células
ATE508205T1 (de) Tests und verfahren unter verwendung von biomarkern
CA2620616A1 (en) Stem cell fusion model of carcinogenesis
Yu et al. Development of the mouse and human cochlea at single cell resolution
EA200501323A1 (ru) Получение эритроцитов с модифицированным уровнем экспрессии антигенов групп крови и их применение в контроле качества реагентов для определения группы крови
Jensen et al. Zinc fixation preserves flow cytometry scatter and fluorescence parameters and allows simultaneous analysis of DNA content and synthesis, and intracellular and surface epitopes
WO2015017784A1 (en) Tissue engineered models of cancers
Munera Lopez et al. An apical protein, Pcr2, is required for persistent movement by the human parasite Toxoplasma gondii
Varberg et al. Quantitative analysis of nuclear pore complex organization in Schizosaccharomyces pombe
ATE513851T1 (de) Menschliches gen zur fruchtbarkeit entscheidend
Bouvrais et al. The coordination of spindle‐positioning forces during the asymmetric division of the Caenorhabditis elegans zygote
WO2019197543A3 (en) Periodontitis diagnostic methods, uses and kits
ATE480774T1 (de) Verfahren und proben zur detektion des tumor spezifische fusion proteinen
WO2006091949A3 (en) Phosphorylated p68 rna helicase as a marker for cancer and cancer metastasis
DE60138192D1 (de) Verfahren zur quantifizierung der akt-protein-expression
WO2021222451A3 (en) Tagged gene editing technology for clinical cell sorting and enrichment
DE60216721D1 (de) Verfahren zum Nachweis von Protein-Proteininteraktionen in Membranen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU